Durect Corporation (DRRX) Shares are Down -18.24%

Durect Corporation (DRRX) : During the past 4 weeks, traders have been relatively bearish on Durect Corporation (DRRX), hence the stock is down -15.81% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -18.37% relative to the S&P 500. The 4-week change in the price of the stock is -16.27% and the stock has fallen -18.24% in the past 1 week.

The stock has recorded a 20-day Moving Average of 12.39% and the 50-Day Moving Average is 19.45%.The 200 Day SMA reached 4.29%


Durect Corporation (NASDAQ:DRRX): After opening at $1.34, the stock dipped to an intraday low of $1.3 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.41 and the buying power remained strong till the end. The stock closed at $1.39 for the day, a gain of 3.73% for the day session. The total traded volume was 1,088,282. The stocks close on the previous trading day was $1.39.

Durect Corporation (DRRX) : The highest short term price target forecast on Durect Corporation (DRRX) is $6 and the lowest target price is $1. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $3.58 with a standard deviation of $2.38.

Durect Corporation is a specialty pharmaceutical company. The Company is focused on the development of pharmaceuticals based on its drug delivery technology platforms, chemical entities derived from its Epigenomic Regulator Program, and its engagement in drug development. Its research and development programs fall into one of two categories: Drug Delivery Programs, in which it applies its formulation and technologies to pharmaceutical ingredients, and New Chemical Entities derived from its Epigenomic Regulator Program, in which it discovers and develops molecules. It also manufactures and sells osmotic pumps and biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. Its product pipeline consists of seven investigational drug candidates in clinical development: REMOXY (ORADUR-Oxycodone), POSIDUR (SABER-Bupivacaine), ELADUR (TRANSDUR-Bupivacaine), Relday, ORADUR-ADHD, ORADUR-Opioid and SABER-based ophthalmic.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *